Dr. Reddy’s Laboratories has launched Atomoxetine Capsules, USP, a therapeutic equivalent generic version of Strattera (atomoxetine) Capsules in the United States market approved by the US Food and Drug Administration (USFDA). The Strattera brand and generic had US sales of approximately $304 million MAT for the most recent twelve months ending in August 2018 according … Read more
Strides Pharma Science’s step‐down wholly owned subsidiary, Strides Pharma Global Pte, has received approval for Gabapentin Capsules USP, 100 mg, 300 mg, and 400 mg from the United States Food and Drug Administration (USFDA). Gabapentin Capsules is a generic version of Neurontin Capsules of Pfizer. The product received approval in the first cycle of review … Read more
Dr. Reddy’s Laboratories has received an approval for Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States market from the US Food and Drug Administration (USFDA). The company is working towards launching the product. The Aggrenox brand and generic had US sales of … Read more
